The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2
Open accessPublished version of a preprint
Abstract
Natural killer (NK) cells are immune cells sensing and eliminating foreign, stressed, transformed, and senescent cells through specialized surface receptors, such as NKG2D, that interacts with several virus- or stress-inducible ligands, including ULBP1 and -2, which are expressed on target cell surfaces. For example, induction of DNA damage or cellular senescence pathways in tumor cells led to upregulation of NKG2D ligands that activate NK cells. Although, both pathways activate p53, the relationship of p53 activation to upregulation of NKG2D ligands has not been addressed. In this study, we report that induction of wild-type p53, but not mutant p53, strongly upregulated mRNA and cell surface expression of ULBP1 and -2, whereas expression of other NK cell ligands was not affected. We defined intronic p53-responsive elements in these two novel p53 target genes. Coculture of wild-type p53-induced human tumor cells with primary human NK cells enhanced NKG2D-dependent degranulation and IFN-γ production by NK cells. Accordingly, treatment of certain wild-type p53-expressing tumor cell lines with the p53-reactivating small molecular compound RITA resulted in upregulation of ULBP2 mRNA and cell surface protein expression. Taken together, our findings define the involvement of p53 in the regulation of specific NKG2D ligands that enhance NK cell–mediated target recognition. One implication of our work is that activating p53 after adoptive transfer of NK cells might constitute an effective combinatorial strategy of NK cell–based immunochemotherapy in cancers in which wild-type p53 function is preserved. Cancer Res; 71(18); 5998–6009. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In brief, the status of genes can influence tumor cells not only through the impact of wild-type gene loss but also through their effects on the TIME.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“Some missense mutant proteins can lose the transcriptional effects of wild-type genes, such as keeping PDL1 expression levels low, thereby making cancer cells more susceptible to cytotoxic T cells and NK cells, limiting the immune system’s ability to attack cancer cells.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“On the other hand, activating wild-type proteins can increase IFNγ signaling and sensitize tumors to immune checkpoint inhibitors, whereas corresponding mutant proteins can reduce the efficacy of immune checkpoint inhibitors.612–614”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“In contrast, two studies reported that pharmacological reactivation of p53 in specific cell lines can stimulate the expression of ULPB2, a ligand for human NKG2D (Li et al., 2011; Textor et al., 2011).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Textor et al., 2011
In the citing paper
“Additional immunostimulatory effects linked to pharmacological p53 reactivation in cancer cells include (but are not limited to) (1) downregulation of immunomodulatory cytokines linked to tumor progression, such as IL6 (Sahin et al., 2020); (2) upregulation of NKALs (Textor et al., 2011); and (3) establishment of cellular senescence linked to an immunostimulatory SASP that favors the recruitment”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Textor et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Recently, it has been shown that reactivation of p53 in mouse cancer models induced rapid tumor regression by the induction of apoptosis or cellular senescence depending on the tumor type (5).”
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J. D., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,674
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W. A., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,394
Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming
Martin‐Fontecha, A., Thomsen, L. L., Brett, S. J., Gerard, C. J., Lipp, M., Lanzavecchia, A., & Sallusto, F. (2004) · Nature Immunology · doi:10.1038/ni1138 · Cited by 1,351
Cited by
Sorted by citations
Items 201–221 of 221
Role of γδ T Lymphocytes in Cancer Immunosurveillance and Immunotherapy
Lança, T., Correia, D. V., & Silva‐Santos, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_13
Boutet, M., Nishitani, K., Erler, P., Couturier, N., Zhang, Z., Militello, A. M., de Miranda, M. C., Barbieux, E., Guillen, E., Suzuki, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.02.510540
Särchen, V. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.70951
Veneziani, I., Infante, P., Ferretti, E., Melaiu, O., Battistelli, C., Lucarini, V., Compagnone, M., Nicoletti, C., Castellano, A., Petrini, S., et al. (2023) · doi:10.1158/2326-6066.c.6550480.v1
Ingelshed, K., Melssen, M. M., Chandramohan, A., Partridge, A. W., Jiang, L., Wermeling, F., Lane, D. P., Nestor, M., & Spiegelberg, D. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4594901
Restoration of Tumor Suppression to Cancer Carrying p53 Mutations
Amin, M. N., & Liu, Y. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003642
Lai, Z., Li, M., Yang, X., & Xian, Z. (2024) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-024-07341-0
张, 健. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551679
Que, L., Liu, Z., Wu, Y., Luo, L., & Liang, L. (2025) · SAGE Open Medicine · doi:10.1177/20503121251341114
Immunothérapie et métabolisme tumorale
Benamor, S. B. (2017) · doi:10.70675/2e5cbde1zb4faz4320zbd12z0a2ba777228b
SLy1-deficiency results in functional impaired, exhausted and senescent NK cells
Rebmann, L., Schwenck, V., Blumendeller, C., Grund, I., Botzenhardt, J., & Beer‐Hammer, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1836862
Increased ULBP1 by doxorubicin sensitizes neuroblastoma to γδT-cell cytotoxicity
Wang, H., Wang, X., Wang, W., Wang, W., Chai, W., Liu, X., Feng, J., Shen, Y., Song, W., 李启亮, et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag144
Amin, M. N., Mostaq, M. S., Jois, S. D. S., Kang, L., & Liu, Y. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48101021
Rusin, M., Krześniak, M., & Łasut-Szyszka, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27208964
Antonov, D., Loguinova, M. Y., Fan, H., Sazonova, E. V., Sosnovtseva, A. O., Karpov, D. S., Molchanov, A. D., Nikolenko, V. N., Chekhonin, V. P., & Mokrysheva, N. G. (2026) · Cells · doi:10.3390/cells15201902
Liu, D., Tang, J., Jiang, Y., Zhao, J., Shen, J., You, L., & Zheng, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1979117
Metadata
- Authors
- Textor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G., & Cerwenka, A.
- Affiliations
- Ben-Gurion University of the Negev (IL)
- Corresponding author
- Cerwenka, Adelheid
- Venue
- Cancer Research
- Published
- 2011-09-13
- Volume
- 71
- Issue
- 18
- Pages
- 5998-6009
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2123143632
- Cited by
- 221
- References
- 36
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 18 · 2023: 13 · 2022: 18 · 2021: 13 · 2020: 19 · 2019: 11 · 2018: 12 · 2017: 10 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 20 · 2012: 13
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- natural killer cells, NKG2D ligands, ULBP1, ULBP2, p53, wild-type p53, p53 target genes, p53 response elements, NK cell cytotoxicity, interferon-gamma, RITA, p53 reactivation
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Furans, Humans, Introns, Killer Cells, Natural, Lung Neoplasms, RNA, Messenger, Up-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Intercellular Signaling Peptides and Proteins, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, NK Cell Lectin-Like Receptor Subfamily K, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
